

## Product datasheet for **TL313686V**

### **CST6 Human shRNA Lentiviral Particle (Locus ID 1474)**

#### **Product data:**

<b>Product Type:</b>	shRNA Lentiviral Particles
<b>Product Name:</b>	CST6 Human shRNA Lentiviral Particle (Locus ID 1474)
<b>Locus ID:</b>	1474
<b>Synonyms:</b>	ECTD15
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>Format:</b>	Lentiviral particles
<b>Components:</b>	CST6 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
<b>RefSeq:</b>	<a href="#">NM_001323</a> , <a href="#">NM_001323.1</a> , <a href="#">NM_001323.2</a> , <a href="#">NM_001323.3</a> , <a href="#">BC031334</a> , <a href="#">BC031334.1</a> , <a href="#">NM_001323.4</a>
<b>UniProt ID:</b>	<a href="#">Q15828</a>
<b>Summary:</b>	The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. This gene encodes a cystatin from the type 2 family, which is down-regulated in metastatic breast tumor cells as compared to primary tumor cells. Loss of expression is likely associated with the progression of a primary tumor to a metastatic phenotype. [provided by RefSeq, Jul 2008]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).